14th Jan 2014 11:39
LONDON (Alliance News) - Clinigen Group PLC said Tuesday that its Clinical Trials Supply Business had extended its exclusive EU clinical trial distribution agreement with Accord Healthcare to include chemotherapeutic tablet capecitabine.
Clinigen is the sole point of contract for all clinical trial supply enquiries for Accord's EU portfolio of more than 15 drugs, after it renewed its agreement with Accord for a further two years in June 2013.
Shares in the pharmaceuticals and services company were trading up 0.2%, or 1.34 pence, at 601.34 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L